{"name":"Mundipharma Research GmbH & Co KG","slug":"mundipharma-research-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Oxycodone & naloxone combination, prolonged release","genericName":"Oxycodone & naloxone combination, prolonged release","slug":"oxycodone-naloxone-combination-prolonged-release","indication":"Moderate to severe pain","status":"phase_3"},{"name":"Oxycodone/Naloxone Prolonged Release tablets","genericName":"Oxycodone/Naloxone Prolonged Release tablets","slug":"oxycodone-naloxone-prolonged-release-tablets","indication":"Chronic moderate to severe pain requiring prolonged opioid therapy","status":"phase_3"},{"name":"oxycodone naloxone tablet","genericName":"oxycodone naloxone tablet","slug":"oxycodone-naloxone-tablet","indication":"Moderate to severe chronic pain in opioid-tolerant patients","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Laxative","genericName":"Laxative","slug":"laxative","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"MR308","genericName":"MR308","slug":"mr308","indication":"Chronic cough","status":"phase_3"}]}],"pipeline":[{"name":"Laxative","genericName":"Laxative","slug":"laxative","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxycodone & naloxone combination, prolonged release","genericName":"Oxycodone & naloxone combination, prolonged release","slug":"oxycodone-naloxone-combination-prolonged-release","phase":"phase_3","mechanism":"Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist.","indications":["Moderate to severe pain","Severe pain for patients who are tolerant to other opioids"],"catalyst":""},{"name":"MR308","genericName":"MR308","slug":"mr308","phase":"phase_3","mechanism":"MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons.","indications":["Chronic cough","Neuropathic pain"],"catalyst":""},{"name":"Oxycodone/Naloxone Prolonged Release tablets","genericName":"Oxycodone/Naloxone Prolonged Release tablets","slug":"oxycodone-naloxone-prolonged-release-tablets","phase":"phase_3","mechanism":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed or dissolved.","indications":["Chronic moderate to severe pain requiring prolonged opioid therapy"],"catalyst":""},{"name":"oxycodone naloxone tablet","genericName":"oxycodone naloxone tablet","slug":"oxycodone-naloxone-tablet","phase":"marketed","mechanism":"Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the tablet is tampered with.","indications":["Moderate to severe chronic pain in opioid-tolerant patients","Abuse-deterrent formulation for reduced misuse risk"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOWUhMX2hkSncyZ1J3Q0JwQ1FwQ2pHZWhVOXdQSXl0V3hqMW5PZzIzWWsxX2F6bmlKTHVGVGQ2UmNLMWN6Wlg4T1ZnaDlqZHZIUW4tVzN6blRiemIyX3dyMkRRdzlJUzhPUnBvamVXUXZ3dHpxbGlMd1AxaEJvTWFxbnlrRzZleXZpYTk0aWZyM1g?oc=5","date":"2024-02-14","type":"regulatory","source":"Frontiers","summary":"Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A Systematic Review - Frontiers","headline":"Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A System","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNd0xfQ0dxa0VhdGNvZ1pjd21Td2ZuSS0zbjNqMWtDU1dmNU5CLV8xUkFsdVR5TjJFQTBrdVdudjg0WGN4QUJrdmNJYnZ2TEVTVnFFTXFxQU5STWdKc21XbkNMM0JuWXpqUTNFVklKcUpzTk4yV21DS2lPR1Yxd0dERWUtc1ExOTRfcF84MWI0MFNiLS1ZclZKM0FBS3dUbndRWU4wLUhHM2xndFRFcHVKak52cVUxWS1MM0NlUUQ5NkF2UEJKY1ZtMTRZbkkxenFYVGstVUw3TnNvUHlaQkNpMlAxeXZwdl8wdkFvQVBmbEV2ZXk5YlYzSkV6dkJ2bm9rb2lGWmVJcEw2czgyZEJscFB2cUdrdlRXcllUbnZVVVNxSUx0M0x6YlA0Z0ZNZ29VTVpXbE9Tdw?oc=5","date":"2024-01-08","type":"trial","source":"GlobeNewswire","summary":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE15Tjc4MmsteklCTkJLejhuYmk2VlZyS3d2eGdLbDlYcF9wTWx3UzdxNndlV0owNFhlbjlQV1lVcFZtb3dlOVlDcUJKcjNfRU1oRTloaGxRSGNpWkNBRXBwWEd1X1NfaWhL?oc=5","date":"2023-09-25","type":"trial","source":"Wiley Online Library","summary":"Subgrouping of facilitatory or inhibitory conditioned pain modulation responses in patients with chronic knee pain. Explorative analysis from a multicentre trial - Wiley Online Library","headline":"Subgrouping of facilitatory or inhibitory conditioned pain modulation responses in patients with chronic knee pain. Expl","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}